公开(公告)号：US11358931B2

公开(公告)日：2022-06-14

申请号：US16983617

申请日：2020-08-03

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/09 ,  C07D207/08 ,  A61P5/28 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/16 ,  A61K31/401

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US11278559B2

公开(公告)日：2022-03-22

申请号：US16557768

申请日：2019-08-30

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  C07F9/6574 ,  C07F9/6584 ,  C07F9/655 ,  C07F9/09 ,  C07F9/6571 ,  A61K9/00 ,  A61K31/661 ,  A61K31/6615 ,  A61K31/663 ,  A61K31/675

Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

公开(公告)号：US10730831B2

公开(公告)日：2020-08-04

申请号：US16148798

申请日：2018-10-01

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  C07D207/09 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/16 ,  A61K31/401

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US10106500B2

公开(公告)日：2018-10-23

申请号：US15590884

申请日：2017-05-09

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  C07D207/09 ,  A61K31/402 ,  C07D498/04 ,  A61K31/5383 ,  A61K45/06

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US09675583B2

公开(公告)日：2017-06-13

申请号：US14827228

申请日：2015-08-14

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/08 ,  A61K31/401 ,  C07D498/04 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/09 ,  C07D207/16

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds, such as compounds, of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

公开(公告)号：US20160347783A1

公开(公告)日：2016-12-01

申请号：US15034757

申请日：2014-11-19

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi

IPC: C07H19/10

CPC classification number: C07H19/10 ,  C07H19/11

Abstract: Some embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

Abstract translation: 本发明的一些实施方案包括核苷5'-单磷酸衍生物化合物，其制备及其用途。 在一些实施方案中，这些化合物可用于治疗丙型肝炎病毒感染。

公开(公告)号：US20160311888A1

公开(公告)日：2016-10-27

申请号：US15206063

申请日：2016-07-08

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Roland Buelow

IPC: C07K16/00 ,  A01K67/027 ,  C12N15/85 ,  C12N5/075

CPC classification number: C07K16/00 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2267/01 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/76 ,  C12N5/0609 ,  C12N9/22 ,  C12N15/8509 ,  C12N2015/8518 ,  C12N2510/00

Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

公开(公告)号：US09359285B2

公开(公告)日：2016-06-07

申请号：US14519053

申请日：2014-10-20

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Robert I. Higuchi ,  Cornelis Arjan Van Oeveren ,  Thomas Lot Stevens Lau

IPC: C07D277/46 ,  A01N43/42 ,  C07C211/52 ,  C07C255/58 ,  C07F7/18 ,  C07D207/27 ,  C07D207/08 ,  C07D209/12 ,  C07D211/60 ,  C07D211/22 ,  C07C205/55

CPC classification number: C07C211/52 ,  C07C205/55 ,  C07C255/58 ,  C07C2601/08 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D207/46 ,  C07D209/04 ,  C07D209/08 ,  C07D209/12 ,  C07D211/22 ,  C07D211/56 ,  C07D211/60 ,  C07D215/04 ,  C07D215/18 ,  C07D265/36 ,  C07D295/073 ,  C07F7/1804 ,  G01N2333/723

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

公开(公告)号：US20160038461A1

公开(公告)日：2016-02-11

申请号：US14827228

申请日：2015-08-14

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: A61K31/401

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract translation: 本文提供了结合雄激素受体和/或调节雄激素受体活性的化合物。 还提供了制备和使用这些化合物的方法。 还提供了包含这些化合物的组合物和用于制备和使用这些组合物的方法。

公开(公告)号：US20160022638A1

公开(公告)日：2016-01-28

申请号：US14775587

申请日：2014-03-10

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  G01N33/50 ,  A61N5/10 ,  A61K45/06

CPC classification number: A61K31/4045 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/454 ,  A61K45/06 ,  A61N5/10 ,  G01N33/5011

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

Abstract translation: 一些实施方案包括用于治疗，预防，逆转，停止或减缓癌症进展的方法，包括向有需要的受试者施用有效量的一种或多种化学治疗剂或其药学上可接受的盐或药物组合物， 其中至少一种化学治疗剂是细胞毒性粒细胞集落刺激因子受体（GCFR）调节剂。 还公开了用于治疗，预防，逆转，停止或减缓造血障碍进展的方法，包括向有需要的受试者施用治疗有效的细胞毒性量的GCFR调节剂。